Management of Acebutolol-Induced Hypotension
Immediately discontinue acebutolol and provide supportive care with intravenous fluids, atropine for bradycardia, and vasopressors if hypotension persists despite volume resuscitation.
Immediate Actions
Discontinue the Offending Agent
Stop acebutolol immediately. The drug is dialyzable, which becomes relevant in severe cases 1.
Initial Supportive Measures
Volume resuscitation should be the first-line intervention:
- Administer intravenous normal saline to correct potential volume depletion
- Beta-blocker-induced hypotension often involves reduced cardiac output and bradycardia rather than pure vasodilation 2
Monitor for symptomatic hypotension (dizziness, lightheadedness) versus asymptomatic blood pressure readings—symptomatic hypotension requires more aggressive intervention 3.
Treating Bradycardia
If bradycardia is present (a common contributor to acebutolol-induced hypotension):
- Atropine 1-3 mg IV in divided doses as first-line therapy 1
- If inadequate response to atropine: Consider isoproterenol cautiously (larger than usual doses may be required due to beta-receptor blockade) 1
- Electrical pacing may be reasonable for refractory bradycardia 4
Managing Persistent Hypotension
After correcting bradycardia, if hypotension persists:
Vasopressor Therapy
Administer vasopressors with frequent monitoring of blood pressure and pulse 1. Options include:
- Epinephrine
- Norepinephrine
- Dopamine
- Dobutamine
The 2023 AHA guidelines recommend vasopressors for beta-blocker-induced hypotension 4, though acebutolol's cardioselectivity and mild intrinsic sympathomimetic activity 2 may make it less severe than non-selective agents.
Glucagon Therapy
Glucagon bolus followed by continuous infusion is reasonable for beta-blocker-induced bradycardia or hypotension 4. Glucagon increases contractility and improves hemodynamics by bypassing beta-receptors 1.
High-Dose Insulin
For refractory hypotension with cardiogenic shock features, high-dose insulin therapy is recommended as it improves inotropy in beta-blocker poisoning 4. This should be administered with dextrose supplementation to prevent hypoglycemia.
Advanced Interventions for Severe Cases
Extracorporeal Support
VA-ECMO may be life-saving for persistent cardiogenic shock refractory to maximal pharmacological support 4.
Hemodialysis
Acebutolol is dialyzable 1. The EXTRIP workgroup suggests hemodialysis for severely poisoned patients with atenolol (a similar hydrophilic, cardioselective beta-blocker) when refractory bradycardia and hypotension are present, particularly with kidney impairment 5. This may be reasonable for acebutolol given similar pharmacokinetic properties, though specific evidence is limited.
Additional Considerations
Cardiac Failure Management
If heart failure develops:
- Digitalize the patient and/or administer diuretics 1
- Glucagon has been reported as useful in this situation 1
Bronchospasm
If present (less likely with cardioselective acebutolol):
- Theophylline derivative (aminophylline)
- Parenteral beta-2 agonist (terbutaline) 1
Common Pitfalls to Avoid
- Do not use intravenous lipid emulsion therapy—it is not likely beneficial for beta-blocker poisoning 4
- Avoid premature discontinuation of supportive care—acebutolol has a half-life of 8-13 hours, and effects may be prolonged 2
- Monitor for hypoglycemia, though this is less common with beta-1 selective agents like acebutolol 4
- Check renal function—acebutolol is 60% renally excreted, and impaired kidney function may prolong effects 2
Monitoring Parameters
- Continuous cardiac monitoring
- Blood pressure (supine and upright if patient stable enough)
- Heart rate
- Urine output
- Serum glucose
- Renal function
The key principle is that acebutolol-induced hypotension requires immediate drug discontinuation, aggressive supportive care starting with volume resuscitation, treatment of bradycardia with atropine, and escalation to vasopressors and advanced therapies as needed based on clinical response.